TG THERAPEUTICS INC (TGTX)

Interesting TGTX Put And Call Options For January 2025

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET...

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast...

Noteworthy Wednesday Option Activity: CVNA, AAP, TGTX

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review

A Fed rate cut and a slew of big earnings reports filled out a busy week.

TG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results

The company raised its sales outlook for the year, though, following stronger-than-expected revenue from its only product.

TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million ...

AI Stocks Meta, Oracle Lead Five Names Near Buy Points

Two of the 5 top stocks to watch this week tap the artificial intelligence market.

As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report

Amid the election, and a Fed rate vote, earnings season roars ahead.

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Conference call to be held Monday, November 4, 2024, at 8:30 AM ET...

RSI Alert: TG Therapeutics (TGTX) Now Oversold

Interesting TGTX Put And Call Options For May 2025

Stock Market Hits Record Highs On Big Fed Rate Cut; Apple, Intel, FedEx In Focus: Weekly Review

TheApple iPhone 16 went on sale amid mixed signals about demand.

IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug

The company unveiled five-year test results for its multiple sclerosis drug, Briumvi.

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate...

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment ...

Interesting TGTX Put And Call Options For November 1st

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations,...